PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphatidylinositol-3 kinase (PI3K) pathway is frequently dysregulated in various cancers, including breast, gastric, and prostate cancers.
• PI3K signaling is critical for cancer cell survival, angiogenesis, and metastasis, positioning it as a key therapeutic target.

Purpose of the Study:

• To review the current landscape of phosphatidylinositol-3 kinase (PI3K) inhibitors in clinical trials for various cancer types.
• To analyze the efficacy, safety, and challenges associated with PI3K inhibitors as monotherapy or combination treatments.
• To highlight novel PI3K-targeting drugs with potential for clinical translation.

Main Methods:

• Comprehensive review of ongoing and completed clinical trials involving pan-PI3K, isoform-specific, and dual PI3K/mTOR inhibitors.
• Analysis of treatment outcomes, drug-related toxicities, and adverse events reported in clinical studies.
• Evaluation of resistance mechanisms and challenges in PI3K inhibitor therapy.

Main Results:

• PI3K inhibitors show promise in various cancer types, with ongoing trials evaluating their efficacy in monotherapy and combination regimens.
• Drug-related toxicities and adverse events are significant challenges impacting treatment outcomes and leading to treatment failure.
• Understanding resistance mechanisms is crucial for optimizing PI3K inhibitor therapy.

Conclusions:

• PI3K inhibitors represent a promising therapeutic strategy for a range of cancers, but careful management of toxicities and overcoming resistance are essential.
• Further research and development of novel PI3K inhibitors are needed to improve clinical outcomes and expand treatment options.